All In Biotech

Drug Trial Radar · NCT02374567

Pharmacovigilance in Gerontopsychiatric Patients

Last checked: Nov 19, 2026Latest source record: Feb 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

407

Actual

Start

Jan 2015

Primary completion

Jun 28, 2017

Study completion Jun 28, 2017

Sponsor

Lead sponsor
Hannover Medical SchoolAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 2, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this multicenter-study is to investigate safety of psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric inpatients. Elderly people are at higher risk for developing side effects under pharmacological treatment due to an altered metabolic situation, higher comorbidity rates and often polypharmacy. Furthermore gerontopsychiatric patients can often not articulate their symptoms clearly, for example due to pronounced cognitive impairment. The aim of the study is to gain valid data of possible adverse drug reaction rates, their potential risk factors and outcome, as well as medical prescription practises. To assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the five participating study sites. At Baseline demographic data, previous and present disorders, use of drugs, previous and present medication, quality of life, cognitive function, physical examination results, laboratory results and ECG will be assessed. Afterwards patients are visited weekly and screened for possible adverse drug reactions. All adverse drug reactions will be coded in the MedDRA-system. In case of a possible serious adverse drug reaction serum levels of all psychotropic substances applicated will be assessed. Drug combinations will be analysed using an established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible adverse drug reactions are documented continually. 2 weeks after discharge from the ward, patients will be contacted by phone to assess catamnestic data.

Conditions

  • Dementia
  • Depression
  • Schizophrenia
  • Psychosomatic Disorders
  • Anxiety Disorders

Interventions

  • PhenobarbitalDrug

  • PhenytoinDrug

  • CarbamazepineDrug

  • OxcarbazepineDrug

  • Valproic AcidDrug

  • LamotrigineDrug

  • TopiramateDrug

  • GabapentinDrug

  • LevetiracetamDrug

  • PregabalinDrug

  • LacosamideDrug

  • ClonazepamDrug

  • BiperidenDrug

  • LevomepromazineDrug

  • FluphenazineDrug

  • PerphenazineDrug

  • PerazineDrug

  • ThioridazineDrug

  • HaloperidolDrug

  • MelperoneDrug

  • PipamperoneDrug

  • BromperidolDrug

  • BenperidolDrug

  • SertindoleDrug

  • ZiprasidoneDrug

  • FlupentixolDrug

  • ChlorprothixeneDrug

  • ZuclopenthixolDrug

  • FluspirileneDrug

  • PimozideDrug

  • ClozapineDrug

  • OlanzapineDrug

  • QuetiapineDrug

  • SulpirideDrug

  • TiaprideDrug

  • AmisulprideDrug

  • ProthipendylDrug

  • RisperidoneDrug

  • AripiprazoleDrug

  • PaliperidoneDrug

  • DiazepamDrug

  • OxazepamDrug

  • LorazepamDrug

  • BromazepamDrug

  • ClobazamDrug

  • AlprazolamDrug

  • HydroxyzineDrug

  • BuspironeDrug

  • Chloral HydrateDrug

  • FlurazepamDrug

  • NitrazepamDrug

  • TriazolamDrug

  • LormetazepamDrug

  • TemazepamDrug

  • MidazolamDrug

  • BrotizolamDrug

  • ZopicloneDrug

  • ZolpidemDrug

  • ZaleplonDrug

  • MelatoninDrug

  • ClomethiazoleDrug

  • DiphenhydramineDrug

  • PromethazineDrug

  • ImipramineDrug

  • ClomipramineDrug

  • OpipramolDrug

  • TrimipramineDrug

  • AmitriptylineDrug

  • NortriptylineDrug

  • DoxepinDrug

  • MaprotilineDrug

  • Amitriptyline oxideDrug

  • FluoxetineDrug

  • CitalopramDrug

  • ParoxetineDrug

  • SertralineDrug

  • FluvoxamineDrug

  • EscitalopramDrug

  • TranylcypromineDrug

  • MoclobemideDrug

  • MianserinDrug

  • TrazodoneDrug

  • MirtazapineDrug

  • BupropionDrug

  • VenlafaxineDrug

  • ReboxetineDrug

  • DuloxetineDrug

  • AgomelatineDrug

  • PyritinolDrug

  • PiracetamDrug

  • DonepezilDrug

  • RivastigmineDrug

  • GalantamineDrug

  • MemantineDrug

  • NicergolineDrug

  • AcamprosateDrug

  • LithiumDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of frequency and severity of adverse eventsTime frame: Participants will be followed for the duration of hospital stay and the follow-up-visit, an expected average of 6 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Bezirkskrankenhaus Augsburg

    Augsburg, Germany

  • Krankenhaus Hedwigshöhe

    Berlin, Germany

  • Hannover Medical School

    Hanover, Germany

  • Asklepios Fachklinikum Lübben

    Lubin, Germany

  • Asklepios Fachklinikum Teupitz

    Teupitz, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.